De novo heme biosynthesis is carried out by the sequential actions of eight distinct enzymes (see Figure  1A) . The first and rate-limiting step of the pathway is catalyzed by the enzyme δ-aminolevulinic acid (ALA) synthase (ALAS), which promotes condensation of glycine and succinyl CoA to form ALA. Mammals have two ALAS genes: the housekeeping gene ALAS-1 is ubiquitously expressed, whereas ALAS-2 is specific to erythroid cells. Given that excess heme is toxic to cells, it is not surprising that the heme biosynthetic pathway is tightly regulated. For example, both the expression and activity of ALAS-1 are inhibited by heme via feedback mechanisms. In addition, heme biosynthesis can be upregulated in response to an increase in demand, perhaps best illustrated by the drug-induced increase in the production of cytochrome P450 family members in the liver, which metabolize drugs. Reflecting the requirement of cytochrome P450 proteins for heme, many drugs concomitantly induce expression of the ALAS-1 gene (Podvinec et al., 2004) . Ironically, such drug-mediated induction of ALAS-1 expression in turn can precipitate a porphyria attack in susceptible individuals.
. Although heme is known to inhibit its own synthesis through negative feedback loops, the molecular mechanisms that underlie the beneficial effects of glucose and the precipitating effects of fasting are not known.
In this issue of Cell, Spiegelman and colleagues report that a transcriptional coactivator called PGC-1α (PPAR γ coactivator 1α) holds the key to unraveling the mystery of acute porphyria attacks, the disease that reputedly incapacitated the British sovereign King George III and induced his episodes of "madness" (Handschin et al., 2005; see the Cell cover). PGC-1α was originally identified by the Spiegelman group from a cDNA library derived from brown fat tissue. These investigators showed that PGC-1α is a cofactor that interacts with the nuclear receptor family member PPAR γ (reviewed in Puigserver and Spiegelman, 2003). In response to cold temperature, its expression is induced in key thermogenic tissues such as brown fat and skeletal muscle. In these locations, PGC-1α plays an important role in adaptive thermogenesis by enhancing the activities of specific transcription factors (including PPAR γ) that regulate the expression of UCP-1, a key molecule that uncouples ATP synthesis from mitochondrial respiration, resulting in heat production (Puigserver and Spiegelman, 2003).
At first glance, there does not seem to be much of a link between the ability of PGC-1α to regulate energy metabolism and its connection with the genetic disease porphyria. Subsequent studies by the Spiegelman group and others revealed that PGC-1α has another important function in energy homeostasis: the regulation of gluconeogeneis in the liver (reviewed in Puigserver and Spiegelman, 2003). The term gluconeogenesis refers to the process of de novo synthesis of glucose from noncarbohydrate precursors (such as pyruvate and alanine) upon prolonged fasting. It takes place principally in the liver and is essential for providing the sugar needed for organs such as the brain. PGC-1α expression in the liver is rapidly induced by fasting (see Figure 1B) Given that fasting is a powerful inducer of acute attacks of porphyria and that PGC-1α is dramatically induced in the liver upon fasting, Handschin et al. were intrigued by the possibility that PGC-1α might mediate ALAS-1 expression induced by fasting. Indeed, an initial time course analysis showed that liver ALAS-1 and PGC-1α exhibited almost identical temporal patterns of upregulation in response to fasting. The authors then . Thus, it is conceivable that PGC-1α could regulate the ALAS-1 promoter through two nonexclusive mechanisms. In the first, PGC-1α interacts with and coactivates NRF-1 bound at the NRF-1 sites, an action that is presumably insulin insensitive. In the second, PGC-1α interacts with and potentiates the activity of FOXO1, which binds to the insulin-response element; this interaction can be disrupted by insulin signaling. Using a variety of molecular approaches-chromatin immunoprecipitation, gelshift and reporter assays, as well as mutagenesis analyses of regulatory elements-the authors convincingly document that this is indeed the case (see Figure 1B) .
To prove the crucial part played by PGC-1α in the metabolic regulation of ALAS-1 in vivo, Handschin et al. generated mice with a liver-specific deficiency in PGC-1α. As expected, fasting induced expression of ALAS-1 as well as PGC-1α in the liver of wild-type animals. In animals with liver-specific PGC-1α deficiency, however, PGC-1α expression was ablated and, importantly, the induction of ALAS-1 expression in the liver was blunted. A similar effect was observed for gluconeogenic genes that depend on PGC-1α for induction of their expression. The authors also examined the induction of ALAS-1 expression by the drug phenobarbital and found that the drug increased the production of liver ALAS-1 mRNA to a similar extent in both wild-type and PGC-1α-deficient animals. As the effect of phenobarbital is mediated by the nuclear receptors PXR and CAR (Podvinec et al., 2004) , this result suggests that these receptors do not require PGC-1α for activation of ALAS-1.
Having demonstrated a critical role of PGC-1α in fasting-induced expression of ALAS-1, the authors probed its functional relevance in porphyria using a chemical model of this disease. Mice were treated with chemicals such as lead that inhibit specific enzymes of the heme biosynthetic pathway (see Figure 1A) resulting in "priming," a condition that mimics the partial loss of function in heme biosynthesis seen in genetic porphyria. Chemical treatment was combined with fasting to precipitate a "porphyria attack" in mice. In a gainof-function experiment, overexpression of PGC-1α by virus-mediated transduction, in combination with fasting and chemical treatment, led to a dramatic increase in expression of ALAS-1. Plasma levels of the porphyrin precursors ALA and PBG were dramatically increased in these animals, to levels comparable to those seen in genetic mouse models of porphyria (Lindberg et al.,  1996) . Thus, ectopic expression of PGC-1α in conjunction with fasting and chemical treatment created a "porphyria attack" in otherwise normal animals. In contrast, wild-type animals subjected to the same fasting and chemical regimen but in the absence of ectopic PGC-1α exhibited a moderate increase in ALAS-1 mRNA and in porphyrin precursors such as ALA. Remarkably, this moderate increase in ALAS-1 and in heme precursors was completely ablated in animals with liver-specific deletion of PGC-1α, suggesting that these animals are protected from the milder "porphyrialike" symptoms induced by the combined fasting and chemical treatment. Taken together, the gain-and lossof-function experiments strongly indicate that PGC-1α is a key factor that mediates the expression of ALAS-1 during porphyria attacks.
Short of directly examining the effects of PGC-1α loss in a genetic mouse model of porphyria, the study by Handschin et al. nevertheless clearly indicates that PGC-1α is the culprit behind the precipitation of porphyria attacks by fasting. Thus, fasting induces expression in the liver of PGC-1α, which then acts as a powerful coactivator for the transcription factors NRF-1 and FOXO1, resulting in enhanced ALAS-1 expression and an increased risk of a porphyria attack (see Figure 1B) . Glucose administration, together with the resulting secondary increase in insulin, ameliorates this risk through two independent mechanisms: first, by directly antagonizing the induction of PGC-1α expression and second, by reducing the association between PGC-1α and FOXO1 (see Figure 1B) .
Given that the power of the sweet treat for porphyria lies in the ability of glucose to tame PGC-1α, one could envisage alternative (less calorific) treatments that could target PGC-1α in the liver directly by, for example, modulating its expression, activity, or its interaction with relevant transcription factors. Although the development of such therapeutics lies in the future, the new study by Handschin et al. represents a vivid example of an initial endeavor in a seemingly unrelated research area (adipocyte metabolism) that has yielded therapeutic insights into a human disease (porphyria). No doubt, future studies will use mouse genetic models of porphyria (Lindberg et al., 1996) to directly examine the function of PGC-1α. It will also be intriguing to test whether loss of PGC-1α would sufficiently dampen the overall activity of the ALAS-1 promoter such that this loss might offer protection from attacks induced by drugs such as phenobarbital despite the fact that these drugs activate ALAS-1 in a PGC-1α-independent manner. 
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